Myasthenia Gravis and Thymoma

Myasthenia gravis is an autoimmune disorder in which the body produces antibodies—most commonly against acetylcholine receptors, and in a significant subset of patients against MuSK—that disrupt signaling at the neuromuscular junction, causing fluctuating muscle weakness that can become life-threatening when it affects breathing. A notable complication is its association with thymoma, a tumor of the thymus gland that appears to play a role in triggering the aberrant immune response, which is why surgical removal of the thymus—thymectomy—has become a central treatment strategy even in patients without a detectable tumor. Researchers are actively working to understand why distinct antibody subtypes produce different clinical profiles and responses to immunotherapy, and whether earlier or more aggressive intervention can improve long-term outcomes. Epidemiological studies are also refining estimates of disease prevalence and identifying patterns across age, sex, and antibody status that may eventually guide more personalized approaches to treatment.

Works

71,406

Total citations

647,906

Keywords

Myasthenia GravisThymic TumorsAutoantibodiesMuSK AntibodiesThymectomyEpidemiology